Petrelintide vs Eloralintide
Petrelintide (ZP8396) and Eloralintide (LY3841136) are the two newest once-weekly amylin compounds in obesity research. Both reported Phase 2 results in the last year. This page compares them as research compounds.
| Petrelintide | Eloralintide | |
|---|---|---|
| Development code | ZP8396 | LY3841136 |
| Molecule | Long-acting amylin analogue | Selective amylin receptor agonist |
| Administration in trials | Once weekly subcutaneous | Once weekly subcutaneous |
| Phase 2 result | Up to 10.7% at 42 weeks (placebo 1.7%) | 9.5% to 20.1% at 48 weeks (placebo 0.4%) |
| Stopped for side effects | 4.8% (placebo 4.9%) | More GI effects at higher doses |
| Next readout | ZUPREME-2 (type 2 diabetes), second half of 2026 | ENLIGHTEN Phase 3 under way |
| Peptx availability | Not stocked, waitlist on its profile | Factory Direct kits; UK single vials on waitlist |
- Development code
- ZP8396LY3841136
- Molecule
- Long-acting amylin analogueSelective amylin receptor agonist
- Administration in trials
- Once weekly subcutaneousOnce weekly subcutaneous
- Phase 2 result
- Up to 10.7% at 42 weeks (placebo 1.7%)9.5% to 20.1% at 48 weeks (placebo 0.4%)
- Stopped for side effects
- 4.8% (placebo 4.9%)More GI effects at higher doses
- Next readout
- ZUPREME-2 (type 2 diabetes), second half of 2026ENLIGHTEN Phase 3 under way
- Peptx availability
- Not stocked, waitlist on its profileFactory Direct kits; UK single vials on waitlist
Same hormone, different design goals
Both compounds mimic amylin, the hormone released with insulin that acts in the hindbrain on satiety and meal size. Native amylin clumps into fibrils, so every analogue in this class is engineered for stability and a once-weekly half-life.
Petrelintide is described as a long-acting amylin analogue built for high chemical and physical stability at neutral pH, and eloralintide as a selective amylin receptor agonist. Petrelintide's results lead on tolerability; eloralintide's lead on the size of the weight reduction.
What the Phase 2 trials show
Results reported in March 2026 showed petrelintide reaching up to 10.7% mean weight reduction at 42 weeks in the ZUPREME-1 trial, against 1.7% with placebo. Discontinuations for side effects were 4.8%, against 4.9% on placebo, and the most effective arm had no vomiting.
Eloralintide's Phase 2, published in The Lancet in November 2025, reached 9.5% to 20.1% at 48 weeks across its dose arms, against 0.4% with placebo. The trials differ in length, population and dosing, so the figures are not a head-to-head comparison.
Where each programme goes next
Petrelintide's second Phase 2 trial, ZUPREME-2 in people with type 2 diabetes, is due to report in the second half of 2026, the Phase 3 ZUPREME programme started at the end of September 2026, and a Phase 2 study combining it with the incretin candidate CT-388 is planned. Eloralintide is in the ENLIGHTEN Phase 3 programme, and its combination with tirzepatide reported a 48-week Phase 2b in September 2026.
Bottom line for research labs
Petrelintide and Eloralintide are the two amylin compounds to watch, and both are now in Phase 3. Eloralintide has the larger published Phase 2 effect; Petrelintide has the cleaner tolerability story, with its type 2 diabetes Phase 2 still to report. For amylin receptor research today, Eloralintide is the better documented of the two.